Newsroom

Major Press Releases

September 12, 2023

CancerVAX Expands Development Pipeline to Include a Universal CAR-T Cell Platform

June 27, 2023

CancerVAX Reports Significant Progress on Universal Cancer Vaccine Development at UCLA

June 12, 2023

CancerVAX Reports Positive Progress on Kids Cancer Immunotherapy Treatment

News Commentary

Thumbnail

February 27, 2024 - CancerVax News Commentary

Thumbnail

February 18, 2024 - CancerVax News

Thumbnail

November 4, 2023 - Bridgette Wilson Sampras

CancerVAX In The News

news November 12, 2023

22 Entrepreneurs Explain What Being a CEO Means to Them

news October 12, 2023

Ryan Davies Shares Insights on CancerVAX and the Future of Cancer Treatment

news October 5, 2023

Challenges and Opportunities in the Treatment of Ewing Sarcoma

news OCTOBER 6, 2023

Santa Barbara firm partners with UCLA for new cancer treatments

news September 26, 2023

18 Entrepreneurs Share Some of The Best Leadership CEO Hacks and Resources

news September 23, 2023

Cancer Vaccines: Where are We Now and Where are We Going?

news August 14, 2023

Serial Entrepreneur Using Science to Tackle the Biggest Disease with Founder Ryan Davies | Ep 693

news July 24, 2023

Labiotech: Sarcoma Research: Is a Breakthrough in Sight?

news July 14, 2023

Healthcare Business Today: Scientists Have Found The Silver Bullet for Pediatric Cancer

news June 22, 2023

HealthLeaders: CancerVax CEO Sees a Homerun With Breakthrough Cancer Vaccine

news July 14, 2023

Scientists Have Found The Silver Bullet For Pediatric Cancer

news JUNE 22, 2023

CancerVax CEO Sees a Home Run With Breakthrough Universal Cancer Vaccine

Press Releases

November 2, 2023

CancerVAX CEO Ryan Davies Discusses Cancer Drug Development with Dr. Ezra Cohen

CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, and Tempus Labs Chief Medical Officer for Oncology Dr. Ezra Cohen, discussed his time at Tempus Labs, Moores Cancer Center and University of Chicago

September 12, 2023

CancerVAX Expands Development Pipeline to Include a Universal CAR-T Cell Platform

CancerVAX, Inc., a pre-clinical biotechnology company working with UCLA to develop breakthrough immunotherapy cancer treatments that use the body’s immune system to fight cancer, today announced an expansion of its development pipeline to include a Universal CAR-T Cell Platform that can dramatically lower the cost of CAR-T cell cancer therapies

August 24, 2023

CancerVAX CEO Ryan Davies Discussed Cancer Immunotherapy with UCLA Physician-Scientist

CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, spoke with and UCLA cancer physician and researcher, Dr. Steven Jonas, about his journey to becoming both a practicing cancer doctor and active cancer researcher

July 25, 2023

World Renowned Biomedical Professor Jonathan Lakey Joins CancerVAX Board of Advisors

Dr. Lakey has been recognized nationally and internationally for his groundbreaking research in cell and tissue transplantation for patients suffering from diabetes and cancer

July 10, 2023

CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan

The two industry leaders focus on navigating the biotech industry and immuno-oncology research

June 27, 2023

CancerVAX Reports Significant Progress on Universal Cancer Vaccine Development at UCLA

Three separate teams of physician scientists at UCLA working on three different parts of the project have made significant progress and are ready to merge their work into a complete proof-of-concept vaccine construct

June 16, 2023

Biotech Executive Michael Smith Discusses the FDA Drug Development Process with CancerVAX CEO Ryan Davies

Michael Smith comments on the growth of immunotherapy and sees the required FDA development phases as a benefit to small biotech firms such as CancerVax

June 12, 2023

CancerVAX Reports Positive Progress on Kids Cancer Immunotherapy Treatment

LEHI, Utah, June 12, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced

May 17, 2023

Biotech Entrepreneur and Venture Capitalist Dinesh Patel Discusses Therapeutics and Medical Devices with CancerVAX CEO Ryan Davies

Lehi, UT – May 17, 2023 – CancerVAX, developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, today reported that the Company’s CEO, Ryan Davies

April 20, 2023

Former Pfizer Legal Counsel Discusses Gene Therapy with CancerVAX CEO Ryan Davies

Stephen Diamond, Senior Vice President, General Counsel, and Secretary of Freeline, discussed his unique path from the legal and business worlds to gene therapy and next-generation therapeutics.

April 12, 2023

CancerVAX CEO Ryan Davies Discusses Cancer Research with Leading Pediatric Hematologic Oncologist

Dr. Satiro De Oliveira, a principal investigator in the Company’s cancer research program at UCLA, comments about the importance of cancer immunotherapy

April 3, 2023

CancerVAX Lands Byron Elton

Experienced business executive to help establish the Company as a significant force in the field of cancer research

March 24, 2023

CancerVax CEO Ryan Davies Speaks with University of Utah Chemistry Professor about the Future of Therapeutic Research

Dr. Ryan Looper, a chemistry Professor at the University of Utah, sat down with CancerVAX CEO Ryan Davies to discuss the future of novel therapeutics and how the industry can encourage young scientists to enter the field.

March 22, 2023

Leading Diabetes Researcher Speaks on his Groundbreaking ‘Edmonton Protocol’ with CancerVAX CEO Ryan Davies

Dr. Jonathan Lakey, Professor in University of California – Irvine’s Surgery and Biomedical Engineering departments, spoke with CancerVAX CEO Ryan Davies on his accomplishments in scientific research and their impact on the world

March 20, 2023

CancerVAX CEO Ryan Davies Sits Down with Oncology Research Leader

Dr. David Bearss, an oncology researcher and biotech start-up founder, spoke with CancerVAX CEO Ryan Davies on the future of oncology therapeutics

March 17, 2023

CancerVax Universal Cancer Vaccine Being Developed by UCLA

The UCLA research team, which includes Dr. Steven Jonas, Dr. Christopher Seet, Dr. Satiro De Oliveira and Dr. Christopher Denny, will leverage cutting-edge technologies to develop a breakthrough universal cancer vaccine (UCV) that will train the body to target and destroy cancer cells.

March 16, 2023

CancerVax Files Non-Provisional Patent for Universal Cancer Vaccine

The Company’s patent application describes how it plans to leverage cutting-edge CRISPR and mRNA technologies to develop a breakthrough universal cancer vaccine (UCV)

August 31, 2022

CancerVAX Announces Research Program to Develop Its Second Immunotherapy Cancer Treatment

The Company has entered into a Sponsored Research Agreement with UCLA to develop a new cancer immunotherapy universal cancer vaccine.

October 6, 2021

CancerVAX Files Provisional Patent for a Universal Cancer Vaccine

The Company plans to leverage cutting-edge CRISPR and mRNA technologies in its quest to develop a breakthrough universal cancer vaccine (UCV).

October 1, 2021

Biotech Executive Joins CancerVAX

New CEO Ryan Davies will lead the Company’s development of its breakthrough immunotherapy treatment SANTA BARBARA, CA – October 1, 2021 – CancerVAX, Inc.

May 26, 2021

CancerVAX Announces Research Program

The Company has entered into an agreement with UCLA to develop an immunotherapy breakthrough targeted at treating Ewing sarcoma, a rare but deadly soft tissue and bone cancer that primarily affects children and young adults.

March 30, 2021

CancerVAX Closes Series A Funding Round

SANTA BARBARA, CA – March 30, 2021 – CancerVAX, Inc., a developer of immunotherapy cancer treatments that use the body’s immune system to fight cancer, today announced it has closed its $2 million series A funding round.

March 23, 2021

CancerVAX Launched

The Company was founded by experienced healthcare executive Lindsay Mann